Mounjaro tirzepatide

Drug Class

Dual GIP and GLP-1 receptor agonist

Mechanism

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that enhances insulin secretion, suppresses glucagon, and delays gastric emptying.

Approved Indication

Treatment of type 2 diabetes mellitus in adults as an adjunct to diet and exercise.

What This Means For Patients

Mounjaro is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2022) — Sources
• EMA — Approved (2022) — Sources
• NMPA — Approved (2024) — Sources

Pivotal Clinical Evidence

• SURPASS-1 — Rosenstock et al., Lancet 2021 (NCT03954834) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro
• http://www.nmpa.gov.cn/